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Abstract
Background—Limited studies exist on the outcome of thrombolytic therapy of acute ischemic 
stroke patients outside of clinical trials.
Aim—To assess the possible risk factors associated with in-hospital death and symptomatic 
intracerebral hemorrhage among patients who received intravenous tissue plasminogen activator.
Methods—A total of 7193 patients with a clinical diagnosis of acute ischemic stroke and a 
documented National Institutes of Health Stroke Scale score were treated with intravenous tissue 
plasminogen activator within 4·5 hours of time last known to be well. Generalized estimating 
equations modeling was used to assess the associations of in-hospital death and symptomatic 
intracerebral hemorrhage with clinical characteristics.
Results—Among 7193 patients treated with intravenous tissue plasminogen activator, 516 
(7·2%) died during hospitalization. Factors associated with in-hospital death were older age, male 
gender, National Institutes of Health Stroke Scale score, history of myocardial infarction or 
coronary artery disease, and history of nonvalvular atrial fibrillation. Increasing age, higher 
National Institutes of Health Stroke Scale score, and history of dyslipidemia were associated with 
symptomatic intracerebral hemorrhage. There was no difference in the rates of in-hospital death or 
symptomatic intracerebral hemorrhage among patients treated with intravenous tissue 
plasminogen activator within three-hours of time last known to be well and those treated between 
three and 4·5 hours after this time.
Conclusions—In this study of acute ischemic stroke patients, older age, male gender, National 
Institutes of Health Stroke Scale score, history of myocardial infarction or coronary artery disease, 
and history of atrial fibrillation were associated with increased in-hospital death among patients 
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receiving intravenous tissue plasminogen activator. Among patients treated with intravenous tissue 
plasminogen activator, in-hospital mortality and symptomatic intracerebral hemorrhage rates were 
similar between those treated within three-hours of time last known to be well and those treated 
between three and 4·5 hours after this time.
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Introduction
Each year, an estimated 795 000 people experience a new or recurrent stroke, and 
approximately 87% of all strokes are ischemic strokes. Intravenous tissue plasminogen 
activator (IV tPA) therapy is the only treatment approved by the Food and Drug 
Administration (FDA) for acute ischemic stroke (AIS), yet the overall use of IV tPA is low, 
ranging from 3·4% to 5·2% of all ischemic strokes in the United States (1,2). IV tPA has 
been shown to improve outcomes after acute ischemic stroke (3). Although several clinical 
trials have examined the complications of IV tPA, studies using large-scale non-clinical trial 
data are limited.
Determining which factors are associated with poor outcomes in a non-clinical trial setting is 
important for understanding the safety of IV tPA in ‘real-world’ experience. Clinical trials 
involving IV tPA had few very elderly (over age 80) patients. In fact, the tPA trial 
conducted by the National Institute of Neurological Disorders and Stroke (NINDS) included 
only 25 patients (of 312) that received IV tPA who were over the age of 80 (4). A recent 
review paper looked at 407 studies on the thrombolytic use of IV tPA and found IV 
thrombolysis was an effective treatment for stroke when delivered under appropriate clinical 
conditions up to 4·5 h from symptom onset (5). While IV tPA is only approved by the FDA 
for use within three-hours of onset of stroke symptoms, many professional organizations 
now advocate the use of IV tPA beyond three-hours (6), with additional cautions for patients 
with a history of both diabetes and prior stroke, patients over age 80, and those with a 
National Institutes of Health Stroke Scale (NIHSS) score over 25.
Aims
The aim of the present study was to assess possible risk factors associated with in-hospital 
death and symptomatic intracerebral hemorrhage (sICH) among patients who received IV 
tPA in the Centers for Disease Control and Prevention’s (CDC’s) Paul Coverdell National 
Acute Stroke Registry (PCNASR) between January 2008 and September 2012.
Methods
Data sources and study sample
Since 2001, the CDC has funded the development and implementation of acute stroke 
quality-of-care registries that are state-centric and hospital based. In 2004, the PCNASR was 
implemented in four state health departments (Georgia, Illinois, Massachusetts, and North 
Carolina), and in 2007, funding was extended to six state health departments (Georgia, 
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Massachusetts, Michigan, Minnesota, North Carolina, and Ohio). The mission of the 
PCNASR is to measure, track, and improve the quality of care and access to care for stroke 
patients from onset of stroke symptoms through rehabilitation and recovery; decrease rates 
of premature death and disability from acute stroke; eliminate disparities in care; support the 
development of stroke systems of care that emphasize quality of care; improve access to 
rehabilitation and opportunities for recovery after stroke; and increase the workforce 
capacity and scientific knowledge for stroke surveillance within stroke systems of care. The 
details of the PCNASR program design have been previously published (7,8).
This analysis included all cases aged 18 and older collected in the PCNASR from January 
2008 to September 2012 with a clinically assigned diagnosis of AIS and a recorded NIHSS 
score that had been treated with IV tPA within 4·5 h after time last known to be well (LKW 
time). Because we used the clinical diagnosis for case identification, International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes were 
not used in this analysis. sICH was defined by a CT scan showing intracranial hemorrhage 
within 36 h of IV thrombolysis and medical record documentation indicating clinical 
deterioration due to hemorrhage. Life-threatening hemorrhage was defined by bleeding 
within 36 hours of IV thrombolysis requiring more than three units of transfused blood 
within seven-days or earlier after receipt of IV thrombolysis or discharge, together with 
medical record documentation that bleeding was the reason for transfusion.
From 2008 to 2012 there were 152 097 patients with a clinical diagnosis of AIS in the 
PCNASR. Among them, 8227 (5·4%) received IV tPA within 4·5 h after LKW time, 
excluding those who received IV tPA at outside hospitals and were subsequently transferred 
to stroke centers. Of these, 1030 (12·5%) patients had missing NIHSS scores and four 
patients had missing gender information; these patients were excluded from the analysis. 
The final study sample was 7193 patients from 209 participating hospitals.
Statistical methods
The differences between categorical variables were examined using two-tailed Fisher’s 
exact or χ2-test, and the differences between continuous variables were examined using the 
Wilcoxon–Mann–Whitney rank test or the Kruskal–Wallis test. To account for the clustering 
of patients within hospitals, generalized estimating equations (GEE) modeling was used to 
assess the association between the outcomes (in-hospital death, sICH) and the prognostic 
factors. The adjusted model included the following covariates: age (<55 years, 55–64 years, 
65–74 years, 75–79 years, 80+ years), gender, race-ethnicity (white vs. other), time of 
receipt of IV tPA (≤3 h vs. 3–4·5 h from LKW time), NIHSS score, hypertension status, 
smoking status, and medical history [dyslipidemia, myocardial infarction (MI) or coronary 
artery disease (CAD), heart failure (HF), diabetes, nonvalvular atrial fibrillation (AF), and 
prior stroke]. We used an upper limit of time from symptom onset to IV tPA initiation of 4·5 
h. Patients with a history of hypertension or taking antihypertensive medication at time of 
the stroke were considered as having hypertension. Adjusted odds ratios (ORs) were 
obtained along with 95% confidence intervals (CIs). A P value of <0·05 was considered 
statistically significant. All analyses were done using SAS software (version 9·2; SAS 
Institute, Cary, NC, USA).
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Among 7193 patients who received IV tPA within 4·5 hours after LKW time, the median 
age was 71 years (range 18–103), and 30·5% of patients were 80 years or older (Table 1). 
Eighty-two percent of patients received IV tPA within three-hours after LKW time, 9% 
received IV tPA between 3 and 3·5 h after LKW time, and 9% received IV tPA between 3·5 
and 4·5 h after LKW time (data not shown). The median NIHSS score was 11 (range 0–42). 
The majority of patients had hypertension, and the other comorbidities are presented in 
Table 1. We found that 5·6% of patients had a history of both diabetes and prior stroke (data 
not shown). The proportion of smokers was 21·4%, and the median length of stay was four-
days (range 0–381). Fifty-two percent of patients were admitted to hospitals with more than 
500 beds, 90·3% of them were treated in a hospital with a stroke unit, and 74·3% of them 
were treated in a teaching hospital (Table 1).
In-hospital death
Among 7193 AIS patients treated with IV tPA, 516 (7·2%) died during the hospital 
admission. Unadjusted analyses showed no variation in the proportion of in-hospital deaths 
in relation to hospital bed size, presence of stroke unit in the hospital, or status as a teaching 
hospital (Table 1). There was no difference in the proportion of in-hospital deaths between 
those receiving thrombolysis within three-hours of LKW time and those receiving 
thrombolysis between 3 and 4·5 h after LKW time (P = 0·34).
Adjusted analyses showed there were five factors associated with the risk of in-hospital 
death. Increased age was associated with an increased risk of in-hospital death. The adjusted 
odds ratio (OR) versus patients <55 years old was 1·73 (95% CI 1·15–2·61, P = 0·008) for 
patients age 65–74, 2·01 (95% CI 1·29–3·13, P = 0·002) for those age 75–79, and 2·92 (95% 
CI 1·99–4·29, P < 0·001) for those age 80 years and older. Males had a higher risk of in-
hospital death than females (adjusted OR of 1·24; 95% CI 1·02–1·52, P = 0·03). The NIHSS 
score was significantly associated with the risk of in-hospital death, with an adjusted OR of 
1·11 (95% CI 1·10–1·13, P < 0·001) for each unit increase. Patients with a history of MI or 
CAD or a history of AF had a higher risk of in-hospital death (adjusted ORs 1·28 and 1·25 
respectively) than those without these comorbidities (Table 3). Further, by looking at 
whether patients were or were not age 80 years or older, at whether they had a history of MI 
or CAD or AF, and at their NIHSS score, we found that patients age 80 years and older with 
a history of AF and a history of MI or CAD had the highest risk of in-hospital death after 
thrombolysis compared with others (Fig. 1).
Hemorrhagic complications of IV thrombolytic therapy
Overall, sICH was observed in 4·5% of patients receiving IV tPA. Compared with patients 
without sICH, patients with sICH were older (median ages 78 vs. 70), had higher NIHSS 
scores (median scores 16 vs. 10), and were more likely to have hypertension (86·4% vs. 
79·7%), a history of dyslipidemia (50·8% vs. 41·6%), a history of diabetes (31·3% vs. 
24·6%), or a history of AF (30·3% vs. 20·2%) (Table 2). Patients who had a history of both 
diabetes and prior stroke had a higher incidence of sICH (7·1%) than those who did not 
(5·5%, data not shown). However, among patients who had sICH, only 11·8% of patients 
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were smokers, as compared with 21·8% among those without sICH. Hemorrhagic 
complication rates did not differ between patients who received tPA within ≤3 h of LKW 
time and those who received IV tPA within 3–4·5 h (Table 2). Adjusted analysis showed that 
increasing age, higher NIHSS score (adjusted OR 1·06; 95% CI 1·05–1·08, P < 0·0001), and 
history of dyslipidemia (adjusted OR 1·34; 95% CI 1·05–1·70, P = 0·02) were associated 
with sICH (Table 3). Patients with a history of both diabetes and prior stroke were not more 
likely to develop sICH (data not shown). Patients with sICH had a higher rate of in-hospital 
death (26·9%) than those who did not develop sICH (6·2%) (Table 2).
Similarly to sICH, life-threatening hemorrhage was more common among older patients 
(median age of 78 vs. 70 for those without it), those with higher NIHSS scores (median 
score of 17 vs. 10 for those without it) and was associated with a greater rate of in-hospital 
death (58·6% vs. 6·8% for those without it, P < 0·0001; Table 2). Only 0·8% of patients 
developed life-threatening hemorrhage, and among the 323 patients who had sICH and the 
58 patients who had life-threatening hemorrhage, 14 had both complications.
Overall, 38·7% of patients were discharged to home, 4·7% to hospice, 2·9% to an acute care 
facility, and 43·5% to other health care facilities (skilled nursing units, long-term care 
facilities, and rehabilitation hospitals) (data not shown). Patients with sICH were less likely 
to be discharged home and more likely to be discharged to hospice and acute care facilities 
(Table 2).
Discussion
We found that, consistent with results from other studies (9,10), in-hospital death among 
ischemic stroke patients who received IV tPA was associated with increasing age and stroke 
severity. Regression analyses showed increasing age, higher NIHSS score, and history of 
dyslipidemia were independent predictors of sICH. These predictors are also used in the 
iScore. The iScore is a scoring tool used to predict the risk of complications from IV tPA, 
developed by Stroke Outcomes Research Canada (http://www.sorcan.ca/iscore/index.html). 
However, although smoking is used by the iScore, we did not find smoking to be positively 
associated with sICH or in-hospital death after thrombolysis (11).
Even though increasing age was an independent risk factor for in-hospital death and sICH, 
several studies have suggested that age alone should not be a barrier to the treatment 
(9,10,12,13). These studies showed that age, particularly for those age 80 years and older, 
was not associated with poor outcome as defined by modified Rankin Scale (mRS) score at 
discharge (9,10,12–15). The IST-3 study, which was a randomized controlled trial, found 
thrombolysis given within six-hours of stroke improved functional outcome as defined by 
the Oxford Handicap Scale (OHS), and the benefit did not seem to be diminished in patients 
80 years and older (16). We were unable to confirm this result because of the lack of 
information on mRS or OHS scores. However, in our study, 31% of patients who received 
IV tPA were over 80 years old; this was much higher than in previous studies (8% in the 
NINDS trial, 19% in the VISTA trial, and 10% in the SITS trial, respectively) (4,12,13). 
Furthermore, we did find that older age, whether analyzed as a continuous variable, a 
stratified variable, or a dichotomous variable with a cut-point of 80 years, was associated 
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with a greater risk of in-hospital death and the development of sICH. A recent study found 
that when the sum of age and the NIHSS score (Sum) was greater than or equal to 100, 
patients receiving IV tPA developed sICH at more than double the rate of those whose Sum 
was less than 100 (17). Similarly, that study found that when Sum was greater than or equal 
to 100, the mortality rate at three-months was four times higher than when Sum was less 
than 100. However, that study only had 36 patients whose Sum was greater than or equal to 
100. In our study, the rates of in-hospital death and sICH were 18·8% and 7·8%, 
respectively, for patients whose Sum was greater than or equal to 100 (n = 1241), compared 
to 4·8% and 3·8%, respectively, for patients whose Sum was less than 100 (n = 5952). 
Patients whose Sum was greater than or equal to 100 had significantly higher rates of in-
hospital death and sICH than those with Sum less than 100 (P < 0·001 for both, data not 
shown).
NIHSS score was a potential predictor for both in-hospital death and sICH for patients 
receiving IV tPA. A recent study by Fonarow et al. indicated the NIHSS score was a 
substantial prognostic factor for short-term mortality, even in the absence of other clinical 
information (18). Several non-US studies also confirmed these findings (19,20). However, 
the completeness of recorded NIHSS scores was a challenge in all studies. In our study, 13% 
of patients who received IV tPA had missing NIHSS scores. In the PCNASR, we have seen 
a rapid improvement in the documentation of NIHSS score among acute ischemic stroke 
patients across the years (from 42% in 2008 to 71% in 2012; P-value for trend was < 0·001, 
data not shown), but the overall rate of documentation of NIHSS score remains sub-optimal. 
We found that a history of MI or CAD and a history of AF were also independent predictors 
of in-hospital death among patients who received IV tPA within 4·5 hours of LKW time, and 
being over 80 with either a history of AF or MI or one of CAD sharply increased the risk of 
in-hospital death after thrombolysis. Few studies looked at the association of a history of MI 
or CAD and mortality, but the rates of AF were comparable with and the association 
between AF and mortality was consistent with those reported in other studies (12–15). A 
German stroke study did not find AF to be an independent predictor of in-hospital mortality 
(unadjusted and adjusted analysis gave P-values of 0·19 and 0·76, respectively), reporting 
that 29·4% of patients who survived had AF, while 34·3% of patients who died had AF (9). 
However, in our study, only 19·5% of patients who survived had AF, which was much lower 
than in the German study. This difference might be due to differences in age distribution 
between the two registries. The patients in the German study were much younger, with only 
23·9% aged ≥75 years, compared with 41·9% in the PCNASR.
Overall, sICH was observed in 4·5% of AIS patients in the PCNASR treated with IV tPA. 
This was much lower than the rates reported by several clinical trials but was comparable 
with results reported in stroke registries (21). One study showed the use of IV tPA for stroke 
in the oldest old (age 85+) did not increase the risk of sICH (22). In that study, the oldest old 
represented only 7%, a much smaller percentage than found in our study (18%, data not 
shown). Because of the small sample size in that study in this age group, there may not have 
been enough power for them to detect a significant difference.
Thrombolysis received in the extended time window (between 3 and 4·5 h from LKW time) 
was not associated with either in-hospital death or complications of thrombolytic therapies; 
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however, this result differs from the CASES registry (23) and several published studies 
(6,16,24). The IST-3 study reported the greatest benefits in patients treated within three-
hours, but there was not enough power to examine decay of benefit with time (16). The 
CASES registry showed there was a trend toward higher rates of death and sICH in patients 
treated within 3–4·5 h as compared with those treated in 0–3 h (22). In the CASES study, 
88% of patients received tPA within three-hours, and the median NIHSS was 13 in the 3–
4·5-h group and 15 in the 0–3 h group. In our study, 82% received tPA within three-hours, 
but the stroke severity was less for patients treated after both time intervals (median NIHSS 
11 for the 0–3-h group and 9 for the 3–4·5-h group, respectively). This may in part account 
for the lack of association between the tPA time window and in-hospital death or sICH in 
our study. Several meta-analyses on trial data from all ECASS trials, the NINDS trial, and 
ATLANTIS suggested that thrombolysis within 3 to 4·5 h of LKW time improved functional 
outcomes but increased sICH rates, though without significantly increasing mortality (6,24). 
However, these studies had far fewer patients than our study. Our study could not control for 
selection bias in the decision to treat with IV tPA, which may explain differences between 
our study and clinical trials, but our study represents real-world experience with IV tPA.
Our study has several limitations. The PCNASR is a quality improvement program focusing 
on in-hospital care, and therefore the results may not be generalizable. The hospitals that 
participated in the PCNASR, as well as the program requirements for participation, changed 
over time. However, we controlled for hospital characteristics through the GEE models to 
minimize the bias. We did not have information on glucose level at the time of admission, 
computed tomography scan results, or whether antihypertensive medications, which have 
been shown in some studies to be related to the development of sICH (25), were required in 
the emergency department prior to administration of IV tPA. In addition, the definition of 
sICH in our study might be different as compared with other studies. Based on the analysis 
published by Gumbinger (26), our definition, which is similar to that used for the NINDS 
trial, may tend to overestimate the occurrence of sICH because it may include more minor 
cases of sICH. It is conceivable that our predictors for the development of sICH might 
change if laboratory and imaging results were included. Finally, regarding the concern that 
registry data are affected by case selection bias, CDC requires that funded states track the 
extent of case abstraction of participating hospitals within the state registries; however, we 
do not conduct a formal national audit of the data using a sole-source abstractor. While the 
potential for case selection bias exists, the majority of hospitals are making every effort to 
abstract all stroke cases. As noted above, we are unable to account for selection bias in the 
decision to treat with IV tPA, but because of that, we can provide information on real-world 
experience in the use of IV tPA. Limitations aside, the strength of this study is that we had a 
large cohort of patients treated in a variety of academic and nonacademic hospitals. Most 
existing studies had small numbers of patients, leading to inconclusive results.
In conclusion, given our findings that age, gender, NIHSS score, history of MI or CAD, and 
history of AF were associated with in-hospital death among AIS patients who received IV 
tPA, we conclude that whether a patient is age 80 or older and whether he or she has a 
history of AF and/or CAD are important factors to consider, along with the NIHSS score, 
when considering the use of IV thrombolysis. Finally, we confirmed significant associations 
between the NIHSS score and both mortality and sICH. While the overall documentation of 
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stroke severity is high and has improved significantly in recent years, additional work needs 
to be done to document stroke severity in all patients receiving IV tPA.
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The predicted probability of in-hospital death among patients receiving intravenous tissue 
plasminogen activator. NIHSS, National Institutes of Health Stroke Scale; AF, atrial 
fibrillation; MI, myocardial infarction.
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Table 1
Characteristics of AIS patients who received IV tPA according to whether they died in the hospital
Variable Overall (n = 7193) Died (n = 516) Survived (n = 6677) P value*
Age (years), median (range) 71 (18–103) 81 (28–100) 70 (18–103) <0·0001
Age group, n (%)
 <55 years 1362 (18·9) 36 (7·0) 1326 (19·9) <0·0001
 55–64 years 1348 (18·7) 56 (10·9) 1292 (19·4)
 65–74 years 1465 (20·4) 86 (16·7) 1379 (20·7)
 75–79 years 821 (11·4) 63 (12·2) 758 (11·4)
 80+ years 2197 (30·5) 275 (53·3) 1922 (28·8)
Male, n (%) 3563 (49·5) 240 (46·5) 3323 (49·8) 0·16
Race-ethnicity, n (%)
 White 5273 (73·3) 403 (78·1) 4870 (72·9) 0·03
 Black 1462 (20·3) 83 (16·1) 1379 (20·7)
 Other 458 (6·4) 30 (5·8) 428 (6·4)
Time from LKW to IV tPA ≤ 3 h, n (%) 5904 (82·1) 432 (83·7) 5472 (82·0) 0·34
NIHSS score, median (range) 11 (0–42) 19 (0–41) 10 (0–42) <0·0001
Medical history, n (%)
 Hypertension 5757 (80·0) 460 (89·1) 5297 (79·3) 0·0001
 Dyslipidemia 3020 (42·0) 217 (42·1) 2803 (42·0) 1·00
 MI or CAD 1880 (26·1) 186 (36·0) 1694 (25·4) <0·0001
 Heart failure 751 (10·4) 90 (17·4) 661 (9·9) <0·0001
 Diabetes 1793 (24·9) 142 (27·5) 1651 (24·7) 0·17
 Atrial fibrillation 1489 (20·7) 187 (36·2) 1302 (19·5) <0·0001
 Prior stroke 1251 (17·4) 98 (19·0) 1153 (17·3) 0·33
Smoker, n (%) 1537 (21·4) 63 (12·2) 1474 (22·1) <0·0001
Length of stay (days), median (range) 4 (0–381) 4 (0–91) 4 (0–381) 0·36
Hospital bed size, n (%)†
 ≤300 1321 (20·1) 96 (20·3) 1225 (20·1) 0·97
 301–500 1813 (27·6) 133 (28·1) 1680 (27·6)
 >500 3429 (52·2) 245 (51·7) 3184 (52·3)
Stroke unit, n (%)† 5927 (90·3) 422 (89·0) 5505 (90·4) 0·97




Information missing for 34 hospitals.
AIS, acute ischemic stroke; IV tPA, intravenous tissue plasminogen activator; LKW, time last known to be well; NIHSS, National Institutes of 
Health Stroke Scale; MI, myocardial infarction; CAD, coronary artery disease.
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